Dr Janice Knowlden

2021

• Fakes, L. , Hutcheson, I. and Knowlden, J. 2021. The role of the glucocorticoid receptor in anti-hormone resistance in breast cancer. The British Student Doctor Journal 5 (1), pp.18-31. (10.18573/bsdj.184)

2011

• Gee, J. M. W. et al. 2011. Antihormone induced compensatory signalling in breast cancer: an adverse event in the development of endocrine resistance. Hormone Molecular Biology and Clinical Investigation 5 (2), pp.67-77. (10.1515/HMBCI.2011.009)
• Hutcheson, I. R. et al. 2011. Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1. Breast Cancer Research 13 (2) R29. (10.1186/bcr2848)
• Knowlden, J. M. et al. 2011. erbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines. Breast Cancer Research 13 (5) R93. (10.1186/bcr3018)

2010

• Knowlden, J. M. et al. 2010. O-36 Recruitment of insulin receptor substrate-1 by erbB3 impacts on IGF-IR signalling in oestrogen receptor-positive breast cancer cells [Abstract]. EJC Supplements 8 (6), pp.13-14. (10.1016/j.ejcsup.2010.06.037)
• Knowlden, J. M. et al. 2010. Recruitment of insulin receptor substrate-1 by erbB3 impacts on IGF-IR signalling in oestrogen receptor-positive breast cancer cells [Abstract]. Breast Cancer Research 12 (S1), pp.S15. (10.1186/bcr2546)

2008

• Knowlden, J. M. 2008. Role of insulin-like growth factor-type 1 receptor (IGF-IR) signalling in tamoxifen-resistant breast cancer. PhD Thesis , Cardiff University.
• Knowlden, J. M. et al. 2008. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance. Breast Cancer Research and Treatment 111 (1), pp.79-91. (10.1007/s10549-007-9763-9)

2007

• Hutcheson, I. R. et al. 2007. Heregulin beta 1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Breast Cancer Research 9 (4) R50. (10.1186/bcr1754)

2006

• Britton, D. J. et al. 2006. Bidirectional cross talk between ER alpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Research and Treatment 96 (2), pp.131-146. (10.1007/s10549-005-9070-2)
• Hutcheson, I. R. et al. 2006. Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy. Endocrine-Related Cancer 13 (S1), pp.S89-S97. (10.1677/erc.1.01279)
• Jones, H. E. et al. 2006. Growth factor receptor interplay and resistance in cancer. Endocrine-Related Cancer 13 (S1), pp.S45-S51. (10.1677/erc.1.01275)

2005

• Knowlden, J. M. et al. 2005. Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: A supporting role to the epidermal growth factor receptor. Endocrinology 146 (11), pp.4609-4618. (10.1210/en.2005-0247)
• Nicholson, R. I. et al. 2005. Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies. The Journal of Steroid Biochemistry and Molecular Biology 93 (2-5), pp.257-262. (10.1016/j.jsbmb.2004.12.006)
• Nicholson, R. I. et al. 2005. Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. Endocrine-Related Cancer 12 (S1), pp.S29-S36. (10.1677/erc.1.00991)

2004

• Jones, H. E. et al. 2004. Insulin-like growth factor-1 receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocrine-Related Cancer 11 (4), pp.793-814. (10.1677/erc.1.00799)
• Nicholson, R. et al. 2004. Chapter 16: beyond antihormones in the targeted therapy of breast cancer. In: Ingle, J. N. and Dowsett, M. eds. Endocrine Therapy for Breast Cancer Proceedings of the 2003 Gleneagles Conference. New York: Marcel Dekker. , pp.249-258.
• Nicholson, R. et al. 2004. Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clinical Cancer Research 10 (1), pp.346s-354s. (10.1158/1078-0432.CCR-031206)
• Rushmere, N. K. et al. 2004. Analysis of the level of mRNA expression of the membrane regulators of complement, Cd59, Cd55 and Cd46, in breast, cancer. International Journal of Cancer 108 (6), pp.930-936. (10.1002/ijc.11606)

2003

• Gee, J. M. W. and Knowlden, J. M. 2003. ADAM metalloproteases and EGFR signalling [Viewpoint]. Breast Cancer Research 5 (5), pp.223-224. (10.1186/bcr637)
• Hutcheson, I. R. et al. 2003. Heregulin-induced AKT activation promotes growth of gefitinib ('Iressa', ZD1839)-treated, tamoxifen-resistant breast cancer cells [Abstract]. Breast Cancer Research and Treatment 82 (S1), pp.S170. (10.1023/A:1026252325164)
• Hutcheson, I. R. et al. 2003. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Research and Treatment 81 (1), pp.81-93. (10.1023/A:1025484908380)
• Knowlden, J. M. et al. 2003. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144 (3), pp.1032-1044. (10.1210/en.2002-220620)
• Nicholson, R. I. et al. 2003. The biology of antihormone failure in breast cancer. Breast Cancer Research and Treatment 80 (S1), pp.29-34. (10.1023/A:1025467500433)

2002

• Gee, J. M. W. et al. 2002. ZD1839 ('Iressa') improves the antitumour activity of tamoxifen ('Nolvadex') and ICI 182, 780 ('Faslodex') in antihormone responsive breast cancer [Abstract]. European Journal of Cancer 38 (S7), pp.S59. (10.1016/S0959-8049(02)80835-8)
• Nicholson, R. I. et al. 2002. Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer. In: Castagnetta, L. et al., Hormone-Related Tumors: Novel Approaches to Prevention and Treatment. Annals of the New York Academy of Sciences Vol. 963.New York: The New York Academy of Sciences. , pp.104-115. (10.1111/j.1749-6632.2002.tb04101.x)

2001

• McClelland, R. A. et al. 2001. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 142 (7), pp.2776-2788. (10.1210/en.142.7.2776)
• Nicholson, R. I. et al. 2001. ZD1839 (Iressa) improves the antitumor activity of tamoxifen (Nolvadex) in antihormone-responsive breast cancer cells [Abstract]. Clinical Cancer Research 7 (S), pp.3766S.
• Nicholson, R. I. et al. 2001. Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocrine-Related Cancer 8 (3), pp.175-182. (10.1677/erc.0.0080175)

2000

• Knowlden, J. M. et al. 2000. A possible divergent role for the oestrogen receptor alpha and beta subtypes in clinical breast cancer. International Journal of Cancer 89 (2), pp.209-212. (10.1002/(SICI)1097-0215(20000320)89:2<209::AID-IJC17>3.0.CO;2-6)

1999

• Seery, L. T. et al., 1999. [Corrigendum] BRCA1 expression levels predict distant metastasis of sporadic breast cancer (vol 84, pg 258, 1999). International Journal of Cancer 84 (5), pp.544-544. (10.1002/(SICI)1097-0215(19991022)84:5<544::AID-IJC18>3.0.CO;2-9)
• Seery, L. T. et al., 1999. BRCA1 expression levels predict distant metastasis of sporadic breast cancers. International Journal of Cancer 84 (3), pp.258-262. (10.1002/(SICI)1097-0215(19990621)84:3<258::AID-IJC10>3.0.CO;2-H)

1998

• Knowlden, J. M. et al. 1998. C-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. Oncogene 17 (15), pp.1949-1957.

1997

• Knowlden, J. M. et al. 1997. Use of reverse transcription-polymerase chain reaction methodology to detect estrogen-regulated gene expression in small breast cancer specimens. Clinical Cancer Research 3 (11), pp.2165-2172.

1996

• Nicholson, R. I. et al. 1996. Pure antiestrogens - The most important advance in the endocrine therapy of breast cancer since 1896?. In: Castagnetta, L. , Nenci, I. and Bradlow, H. L. eds. Basis for Cancer Management. Annals of the New York Academy of Sciences Vol. 784.New York: New York Academy of Sciences. , pp.325-335. (10.1111/j.1749-6632.1996.tb16247.x)

1995

• Manning, D. L. et al., 1995. Differential expression of estrogen-regulated genes in breast-cancer. Acta Oncologica 34 (5), pp.641-646.